Shares of Daré Bioscience, Inc. (DARE) surged over 135% on Monday morning after the company announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene, the company's investigational monthly, hormone-free intravaginal contraceptive.
DARE is currently trading at $5.95, up $3.44 or 136.51%, on a huge volume of 45.3 million shares, above average volume of 163 thousand, on the Nasdaq. The stock opened its trading at $7.93 after closing Friday at $2.52. The stock has traded between $2.11 and $9.19 in the past 52-week period.
There currently are no FDA-approved, hormone-free, monthly intravaginal contraceptives.
The trial's independent Data Safety Monitoring Board (DSMB) conducted a planned interim analysis focused on reviewing safety data from the study, and recommended the study continue without modification.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.